What Is Mounjaro? Tirzepatide for Type 2 Diabetes Guide

The Quick Answer: What Is Mounjaro?

Mounjaro (tirzepatide) is a once-weekly injectable prescription medication FDA-approved for type 2 diabetes in adults. Manufactured by Eli Lilly, it is the first dual GIP and GLP-1 receptor agonist, a class of drug that improves blood sugar control by stimulating insulin release, suppressing glucagon, slowing digestion, and reducing appetite.

Key facts at a glance:

• Active ingredient: tirzepatide (LY3298176)
• Drug class: dual GIP/GLP-1 receptor agonist (incretin mimetic)
• Administration: subcutaneous injection, once weekly, via the KwikPen autoinjector
• FDA-approved indication: type 2 diabetes (T2D) in adults, as an adjunct to diet and exercise
• Manufacturer: Eli Lilly and Company

What Is Mounjaro Used For?

Mounjaro is approved to improve glycemic control in adults with type 2 diabetes, used alongside diet and exercise. It lowers HbA1c, a blood marker of long-term glucose control, and is not insulin, though it can be prescribed in combination with other diabetes medicines under physician supervision.

One point worth being explicit about: although Mounjaro produces significant weight loss in clinical trials, the brand is not FDA-approved for weight loss. Eli Lilly markets Zepbound (also tirzepatide) for chronic weight management. Some prescribers use Mounjaro off-label for weight loss, but the on-label use is type 2 diabetes.

Mounjaro's FDA Approval History

• May 13, 2022: Mounjaro receives FDA approval for type 2 diabetes (NDA 215866).
• November 2023: Zepbound, the same molecule under a separate NDA, is approved for chronic weight management.
• Subsequent label expansions have broadened use into adolescents aged 10 and older with T2D, per the current FDA label.

What Mounjaro Does Not Treat

• Not approved for type 1 diabetes
• Not approved for diabetic ketoacidosis
• Not a replacement for insulin in insulin-dependent patients
• Not approved for weight loss as a primary indication (that is the Zepbound label)

How Does Mounjaro Work? The Dual Agonist Mechanism

Mounjaro works by mimicking two natural gut hormones at once: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both are incretins, meaning they are released after a meal and help regulate blood sugar. By activating both receptors with one molecule, tirzepatide produces a more layered effect than GLP-1-only drugs.

On the GLP-1 side, tirzepatide stimulates insulin release when glucose is high, suppresses glucagon (the hormone that raises blood sugar), slows gastric emptying so meals are absorbed more gradually, and reduces appetite through brain pathways. On the GIP side, it adds a complementary incretin effect that appears to amplify insulin secretion and modulate how the body handles fat. The combined action is why Mounjaro reduces HbA1c more than older single-receptor agonists in head-to-head trials.

Mounjaro activates both GIP and GLP-1 receptors, producing complementary effects on insulin, glucagon, gastric emptying, and appetite.

GLP-1 vs GIP Receptors: Why Both Matter

GLP-1 and GIP each have their own receptor and their own pattern of effects. GLP-1-only drugs (Ozempic, Wegovy, Trulicity) bind one of those receptors. Tirzepatide binds both. Retatrutide, an investigational drug, goes a step further by adding a glucagon-receptor target on top of GIP and GLP-1. So the family sits on a spectrum: GLP-1 only, then dual GIP/GLP-1 (Mounjaro and Zepbound), then triple agonists like retatrutide.

Mounjaro's Half-Life and Duration of Action

Tirzepatide has a half-life of approximately 5 days. That long elimination time is what allows once-weekly dosing: drug levels do not crash between injections. After 4 to 5 weeks at any given dose, steady state is reached and weekly peaks and troughs stabilize. The tirzepatide pharmacokinetic calculator lets you plot exactly what that curve looks like for your own dose plan, including ramp-up weeks where levels are still climbing.

Mounjaro Dosing: 2.5 mg to 15 mg Titration Schedule

The FDA-labeled Mounjaro dose ladder starts low and climbs in 2.5 mg steps. Each step lasts 4 weeks, and the climb only continues as the previous step is tolerated. The maximum maintenance dose is 15 mg weekly. Not every patient reaches the top; many stay at 7.5 mg, 10 mg, or 12.5 mg if HbA1c targets are met and side effects are stable.

Source: FDA Mounjaro Prescribing Information, NDA 215866.

The standard Mounjaro titration climbs in 2.5 mg increments every 4 weeks, with 15 mg as the maintenance ceiling.

How to Inject Mounjaro (KwikPen)

• Device: KwikPen single-dose autoinjector, pre-filled with the prescribed dose
• Sites: abdomen, thigh, or upper arm. Rotate weekly.
• Timing: any day of the week, with or without food. Pick a day and stay consistent.
• Storage: refrigerate. Let the pen reach room temperature before injecting. Do not freeze.
• Missed dose: follow the FDA label window. If close to the next scheduled dose, skip and resume normally.

For a week-by-week chart with column-by-column dose tracking, see the Mounjaro dosage chart.

What Do the Clinical Trials Show?

Mounjaro's FDA approval rests on the SURPASS phase 3 program in type 2 diabetes. Separate SURMOUNT trials covered tirzepatide for obesity and became the basis for the Zepbound approval. The numbers below are the most cited.

Mounjaro for Type 2 Diabetes (SURPASS-1)

SURPASS-1 was the pivotal monotherapy trial. Over 40 weeks in adults with T2D managed on diet and exercise alone, tirzepatide reduced HbA1c by 1.87% to 2.07% across the three dose arms versus placebo. At the 15 mg dose, 52% of participants reached an HbA1c below 5.7%, which is the non-diabetic threshold. Source: Rosenstock J et al., Lancet 2021;398(10295):143-155.

Mounjaro for Weight Loss (SURMOUNT-1)

SURMOUNT-1 tested tirzepatide in adults with obesity who did not have diabetes. At 72 weeks on the 15 mg dose, participants lost an average of 20.9% of body weight, and 57% lost at least 20%. These results led to the Zepbound approval for weight management. Mounjaro is the same molecule, so the same metabolic effects apply, but Mounjaro's label is type 2 diabetes, not obesity.

How Mounjaro Compares to Ozempic (SURPASS-2)

SURPASS-2 ran tirzepatide head-to-head against semaglutide 1 mg in adults with T2D. Tirzepatide 15 mg reduced HbA1c by 2.30 percentage points versus semaglutide 1 mg at 1.86 percentage points, a difference of 0.44 in favor of tirzepatide. The 15 mg arm also lost about 5.5 kg more body weight than the semaglutide arm. One caveat: the comparator was the diabetes dose of semaglutide (1 mg), not the higher 2.4 mg obesity dose used in Wegovy. See the tirzepatide vs semaglutide comparison for a deeper breakdown.

Mounjaro Side Effects

Most side effects are gastrointestinal and tend to peak when the dose increases. They are usually mild to moderate and improve after a few weeks at the new dose. The 4-week titration interval exists in large part to give the gut time to adapt.

Common Side Effects (GI)

• Nausea (the most frequent, especially right after a dose increase)
• Diarrhea
• Constipation
• Vomiting
• Decreased appetite
• Upper abdominal discomfort

For a full breakdown of timing, severity, and management strategies, see the complete Mounjaro side effects guide.

Serious Side Effects and Contraindications

• Pancreatitis: use caution with prior history; discontinue and evaluate if suspected.
• Diabetic retinopathy: rapid improvement in glucose can transiently worsen retinopathy; baseline eye exam is reasonable.
• Hypoglycemia: low risk on its own, but the risk rises when combined with insulin or sulfonylureas. Dose adjustment of those agents may be needed.
• Gallbladder disease: reported across the GLP-1 class.
• Acute kidney injury: mostly secondary to dehydration from severe GI side effects.

Mounjaro vs Zepbound: Same Molecule, Different Brands

This is the single most common point of confusion. Mounjaro and Zepbound are both tirzepatide, both made by Eli Lilly, both dosed identically. What differs is the FDA-approved indication, the brand of the box on the pharmacy shelf, and the way insurance covers it.

• Mounjaro is labeled for type 2 diabetes (approved 2022).
• Zepbound is labeled for chronic weight management in adults with obesity, plus obstructive sleep apnea in adults with obesity (approved 2023 and later).
• Doses, schedule, pharmacokinetics, side effects: identical.
• Insurance coverage differs by diagnosis. Commercial plans that cover Mounjaro for T2D may not cover Zepbound for weight loss, and vice versa.

For the side-by-side breakdown of formulations, vial-vs-pen options, and cost differences, see how Mounjaro and Zepbound differ.

Who Is Mounjaro For?

Per the FDA label, Mounjaro is approved for adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control. The medication is prescription-only. Candidates typically already have a diabetes diagnosis and a treatment plan that may include metformin or other oral antidiabetics. Mounjaro is not appropriate for type 1 diabetes, for diabetic ketoacidosis, or as a substitute for insulin in patients who depend on insulin.

A few decision points worth raising with a clinician: prior thyroid or pancreatic disease, gallbladder history, current insulin or sulfonylurea use, and plans for pregnancy. Cost and insurance coverage also shape the conversation; for the full breakdown of 2026 pricing, see how much Mounjaro costs in 2026.